TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THAILAND BLOOD PLASMA MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 THAILAND BLOOD PLASMA MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELING
2.8 PRODUCTS LIFELINE CURVE
2.9 SECONDARY SOURCES
2.10 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING PREVALENCE OF BLOOD PLASMA DISORDERS
3.1.2 INCREASING GERIATRIC POPULATION
3.1.3 RISING DEMAND OF BLOOD PLASMA DERIVATIVES PRODUCTS
3.2 RESTRAINTS
3.2.1 HIGH COST OF PLASMA THERAPY
3.2.2 EASY AVAILABILITY OF RECOMBINANT PLASMA
3.3 OPPORTUNITIES
3.3.1 INCREASING IN AWARENESS ABOUT BLOOD & PLASMA DONATION
3.3.2 TECHNOLOGICAL ADVANCEMENT IN IMMUNOGLOBULIN
3.4 CHALLENGE
3.4.1 STRINGENT REGULATORY REQUIREMENTS
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
?
6 THAILAND BLOOD PLASMA MARKET, BY TYPE
6.1 OVERVIEW
6.2 IMMUNOGLOBULIN
6.2.1 SUBCUTANEOUS IMMUNOGLOBULIN (SCIG)
6.2.2 INTRAVENOUS IMMUNOGLOBULIN (IVIG)
6.2.3 OTHER IMMUNOGLOBULINS
6.3 ALBUMIN
6.4 COAGULATION FACTOR CONCENTRATES
6.4.1 PROTHROMBIN COMPLEX CONCENTRATE
6.4.2 FACTOR XIII
6.4.3 FACTOR VIII
6.4.4 FACTOR IX
6.4.5 FIBRINOGEN CONCENTRATES
6.4.6 VON WILLEBRAND FACTOR
6.5 PROTEASE INHIBITORS
6.6 OTHER PLASMA PRODUCTS
7 THAILAND BLOOD PLASMA MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 HEMATOLOGY
7.3 CRITICAL CARE
7.4 IMMUNOLOGY
7.5 PULMONOLOGY
7.6 HEMATO-ONCOLOGY
7.7 RHEUMATOLOGY
7.8 NEUROLOGY
7.9 OTHER APPLICATIONS
8 THAILAND BLOOD PLASMA MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 CLINICS
8.4 CLINICAL RESEARCH LABORATORIES
8.5 ACADEMIC INSTITUTES
9 THAILAND
9.1 THAILAND
10 THAILAND BLOOD PLASMA MARKET, COMPANY LANDSCAPE
10.1 COMPANY SHARE ANALYSIS: THAILAND
11 COMPANY PROFILE
11.1 CSL LIMITED
11.1.1 COMPANY SNAPSHOT
11.1.2 REVENUE ANALYSIS
11.1.3 PRODUCT PORTFOLIO
11.1.4 RECENT DEVELOPMENT
11.2 GRIFOLS, S.A.
11.2.1 COMPANY SNAPSHOT
11.2.2 REVENUE ANALYSIS
11.2.3 PRODUCT PORTFOLIO
11.2.4 RECENT DEVELOPMENT
11.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
11.3.1 COMPANY SNAPSHOT
11.3.2 REVENUE ANALYSIS
11.3.3 PRODUCT PORTFOLIO
11.3.4 RECENT DEVELOPMENT
11.4 OCTAPHARMA AG
11.4.1 COMPANY SNAPSHOT
11.4.2 REVENUE ANALYSIS
11.4.3 PRODUCT PORTFOLIO
11.4.4 RECENT DEVELOPMENT
12 QUESTIONNAIRE
13 RELATED REPORTS